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With the cost of DNA sequencing decreasing rapidly, it is
likely that the genome sequences of many individuals will be
determined. In fact, if half of the individuals in industrialized
countries choose to have their genomes sequenced, then well
over 500 million personal genome sequences will be determined.
Currently, such genetic information is likely to be of limited value
to the individual, as the number of loci that provide useful pre-
dictiveinformationisquitesmall(probablylessthan200).Indeed,
recent analyses of common complex traits such as diabetes, body
mass and height show that in each case the genetically identi-
ﬁable contribution from multiple candidate loci (18 in the case of
diabetes) is only a small percentage (less than 7%) of the total
identiﬁable genetic load (Gaulton et al, 2008; Willer et al, 2009);
thus, the interpretable genetic contributions that can be identiﬁed
are quite minor. Presumably, either many low-frequency alleles at
different loci contribute to the genetic load or perhaps the many
phenotypes are because of other phenomena such as synergistic
effects between variants at more than one locus or between
different loci and factors in the environment, recurrent sponta-
neous mutations, or epigenetic defects.
Regardless of which proves to be correct (likely a differing
mixture of effects for different diseases), the ability to accu-
rately correlate all bases with precise phenotypes is likely to be
powerful only if a common set of phenotypes are scored. The
power of 500 million sequences correlated with 500 million
phenotypes can show both small contributions as well as help
identify potential causative mutations. Indeed, a data set of this
size would greatly exceed that of even the large genome-wide
association studies that typically analyze thousands of individ-
uals to tens of thousands of individuals (Willer et al, 2009).
Although in the short term this information is not likely to be
helpful for prediction of common diseases, it may provide a
generic tool for interpretation and prevention of a large number
of individually uncommon or rare recessive disorders. In the
long term, it is likely to be of enormous value to scientists for
understanding which types of genes and pathways are involved
in a particular biological process and for determining the
underlying nature of complex diseases. Furthermore, the entire
community is expected to ultimately beneﬁt from this informa-
tion,whichwouldhelpinthediagnosisandtreatmentofdisease.
The need for phenotypes to go with
genotypes
Although the prospects of a large number of genome seq-
uences might seem daunting, the biggest stumbling block for
a genotype–phenotype correlation is not likely to be the
acquisition of the DNA sequence, but rather the phenotypic
information. Indeed, the phenotyping of large numbers of
individuals might well prove to be more expensive, complex
and difﬁcult to implement than the genomic sequencing.
However, without common and accurate phenotypes the
power of the genome sequences will be extremely limited.
Deciding exactly what to phenotype is not trivial. Some
types of information, such as height, body mass, blood
pressure, and many aspects of medical history (infectious
and other diseases, etc) are quite common and obvious.
Furthermore, much of this information is already available
(albeit not always consistently obtained or available in a use-
ful manner) (Table I). Other types of information, such as
anatomical features and skeletal information, could be
digitized and converted into useful format for morphometrical
analysis. Phenotypes that would be particularly powerful to
analyze using large data sets are behavioral (e.g. anxiety,
depression) and cognitive attributes (e.g.‘intelligence tests’).
Some of these data are likely to be controversial and raise
issues regarding safeguarding the privacy of information.
Nonetheless, the larger the collection of phenotypes, the more
powerful the genetic information. In order to be useful, these
phenotypes must be stored electronically and in a manner in
which quantitative information can be obtained. In this
respect, having all medical records and information stored in
a digital format would be extremely valuable for sharing and
analyzing data.
Perhaps, even more important than the phenotypes that
should be measured are the implementation of common
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Table I Examples of data types to consider for collection
General Anatomical, height, body mass
Blood pressure
Morphometric
Medical History (disease conditions, medical
treatment, medication, etc. asthma, infections,
cancer, other diseases)
Behavioural &
Cognitive
Anxiety, depression, hyperactivity, sleep
Cognitive attributes (learning and memory,
‘intelligence’)
Molecular
a RNA expression
Proteomics (mass spectrometry; antibody proﬁling)
Metabolomics
Microbiome metagenomics
aTypes of samples to analyze: saliva, plasma, serum, urine, breath, skin (stem
cells), feces (microbiology).
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www.molecularsystemsbiology.commethods and standards for their collection. Phenotypic
data are only likely to be useful if the same types of
information are obtained, and only if the samples and
measurements are obtained using the same methodology.
Many parameters such as medical and psychiatric histories
and physical examinations are not always collected under
comparable conditions or with similar rigor. Although it may
be difﬁcult to have a common method used in all cases, ideally
aprioritizedsetofstandardscouldbeprepared,andminimally
it will be essential to record the types of methods used for each
sample.
Molecular omic phenotypes
One way to provide a larger quantity of phenotypic informa-
tion and potentially in a more standardized format is to shift
from measuring macroscopic properties to analyzing mole-
cules. In addition, the quantities of molecules are expected to
be responsible for the observable bodily phenotypes, and
molecules can be more directly related to the genomic
sequence and its variations.
Traditionally, only a limited number of molecular markers
are monitored, typically during blood tests. However, it is
likely that large-scale and precise measurements of gene
expression or protein abundance in speciﬁc types of cells
are more consistent indicators of a given organism’s pheno-
type. One can accurately quantify the RNA levels of all genes
and/or exons using DNA microarrays or RNA sequencing
(Wang et al, 2009), and the levels of many thousands of
proteins and their modiﬁcations can be followed using mass
spectrometry (Aebersold and Mann, 2003) and ultimately
might be quantiﬁed using afﬁnity reagents. Hundreds of
metabolites can also be monitored using mass spectrometry
(e.g. see Sreekumar et al, 2009). These components can easily
be measured in blood samples, and proteins and metabolites
can be measured in urine. Other samples such as saliva and
breath could also be possibly measured. In the future, one
could even consider the analysis of patient-derived stem cells
and microbiome samples from oral and fecal samples. The
analysis of microbiome using metagenomic sequencing could
prove to be a useful indicator of both environment and
phenotype.
Although RNA and metabolites might be relatively straight-
forward, analysis of proteins in complex samples such as
plasma, sera and urine may be particularly susceptible to how
the samples are prepared, which can have a signiﬁcant
inﬂuence on the outcome. For example, a recent proteome
analysis of human sera showed signiﬁcant differences in
outcome depending upon the buffers and inhibitors present in
the collection samples (Omenn et al, 2005). Nonetheless,
robust analytical procedures need to be established to ensure
that the results can be reproduced in different laboratories.
Furthermore, even if comprehensive monitoring of molecular
markers is difﬁcult, accurately quantifying even a large subset
is likely to be extremely valuable.
The collection of molecular phenotypes is expected to be
extremelyvaluableforhelpingusunderstandthebasicmecha-
nisms involved in human disease. For example, activation of
signaling pathways can be readily deduced from RNA and
protein expression and post-translational modiﬁcation data.
This in turn can be related to the genome sequence. In
addition, molecular information will greatly facilitate medical
diagnostics.Currently, diagnostictestsarecarriedout on small
numbersofproteinswhose functions areusually,although not
always, known. One can readily envision a future in which
simple blood or urine tests involving proﬁling of thousands of
protein and/or metabolic components will be much more
valuable for both early and accurate diagnostics. Control
experiments will obviously have to be carried out to account
for parameters such as diet and the time of day at which the
samples are collected. Nonetheless, such an information is
expected to be extremely useful in conjunction with genomic
and epigenomic analyses.
Moving forward
Several large consortia have formed around global genome
sequencingprojectssuchasthe1000GenomesProjectandThe
Cancer Atlas Project. Although smaller advisory committees
have discussed the collection of common phenotypes (see
Church, 2005), a large consortium is needed to decide what
common phenotypes and samples should be collected and
how would they be of equal impact. Arguably, the best way
to accomplish this is in conjunction with organization of
the large genome sequencing projects. The effort involved in
obtaining a standard set of phenotypes should be no less than
that expended in developing a standard set of gene functions
through the Gene Ontology consortium.
There is no doubt that a large number of human genome
sequences will be a valuable resource. However, it will only
be valuable in the context of a large number of accurate
phenotypes. With the ﬁrst sequences now being determined,
we need to aggressively develop guidelines for deciding what
phenotypes should be collected and establish common
standards for collecting those phenotypes.
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